neobookRx
GuidelinesOther guideline

References

These are the approved guidelines published by the South African Society of Psychiatrists to provide an overview on treatment and management of commonly diagnosed psychiatric illnesses. The guidelines include consensus recommendations, based on peer contribution and using the international evidence based guidelines that are suitable for the local South African health service.

Please note that parts of this guideline may be out of date, an update will be published as soon as it is available.

  1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602. [http://dx.doi.org/10.1001/archpsyc.62.6.593]
  2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627. [http://dx.doi.org/10.1001/archpsyc.62.6.617]
  3. Schneier FR. Social anxiety disorder. BMJ 2003;327:515-516. [http://dx.doi.org/10.1136/bmj.327.7414.515]
  4. Westenberg HGM. Recent advances in understanding and treating social anxiety disorder. CNS Spectrums 2009;14:24-33.
  5. Schneier FR, Johnson J, Hornig CD, et al. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-288. [http://dx.doi.org/10.1001/archpsyc.1992.01820040034004]
  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.7. 
  7. Ruscio AM, Brown TA, Chiu WT, et al. Social fears and social phobia in the USA: Results from the National Comorbidity Survey Replication. Psychol Med 2008;38:15-28.
  8. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: Results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:629-640. [http://dx.doi.org/10.1001/archpsyc.62.6.629]
  9. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-596. [http://dx.doi.org/10.1177/0269881105059253]
  10. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive compulsive and post-traumatic stress disorders – first revision. World Journal of Biological Psychiatry 2008;9:248-312.[http://dx.doi.org/10.1080/15622970802465807]
  11. Van Ameringen M, Allgulander C, Bandelow B, et al. WCA recommendations for the long-term treatment of social phobia. CNS Spectrums 2003;8:40-52.
  12. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders.Can J Psychiatry 2006;51:9S-91S.
  13. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review.Expert Rev Neurother 2008;8(2):235-257 [http://dx.doi.org/10.1586/14737175.8.2.235]
  14. Hedges DW, Brown BL, Shwalb DA, et al. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: A meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 2007;21:102-111.
  15. Allgulander C, Mangano R, Zhang J, et al. SAD 388 Study Group. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Human Psychopharmacology 2004;19:387-396.
  16. Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial.Psychopharmacology 2005;177:280-288.
  17. Stein DJ, Cameron A, Amrein R, et al. Moclobemide Social Phobia Clinical Study Group. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacology 2002;17:161-170.
  18. Blanco C, Raza MS, Schneier FR, Liebowitz MR. The evidence-based pharmacological treatment of social anxiety disorder. International Journal of Neuropsychopharmacology 2003;6:427-442.
  19. Ponniah K, Hollon SD. Empirically supported psychological interventions for social phobia in adults: A qualitative review of randomized controlled trials. Psychol Med 2008;38:3-14.
  20. Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep 2010;12:96-103. [http://dx.doi.org/10.1007/s11920-010-0098-6]
  21. Hitchcock CA, Chavira DA, Stein MB. Recent findings in social phobia among children and adolescents. Isr J Psychiatry Relat Sci 2009;46:34-44.
  22. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with anti-depressant drugs. Arch Gen Psychiatry 2006;63(3):332–339.
  23. Sheikh JI, Cassidy EL. Treatment of anxiety disorders in the elderly: Issues and strategies. J Anxiety Disord 2000;14:173-190.
  24. Schneier FR, Blanco C, Campeas R, et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress Anxiety 2003;17:191-196.
  25. Stein DJ, Stein MB, Pitts CD, et al. Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002;63:152-155.
  26. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39:115-121.
  27. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1725-1727. [http://dx.doi.org/10.1176/appi.ajp.158.10.1725]
  28. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004;65:244-248.
  29. Segool NK, Carlson JS. Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety 2007;25:620-631.
  30. Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010;67:286-295. [http//:dx.doi.org/10.1001/archgenpsychiatry.2010.11]

Drugs mentioned

NeoHealth® ID 17487 · updated 4/20/2022